Capture all cancer mutation types with Archer's Comprehensive Kits
Archer® FusionPlex® and VariantPlex™ assays generate target-enriched libraries for next-generation sequencing (NGS) based mutation detection. These assays vary in their starting material but both use Anchored Multiplex PCR (AMP™) chemistry for target amplification. The FusionPlex and VariantPlex Solid Tumor panels combined provide a comprehensive targeted sequencing approach to detect various driver mutation types in solid tumors. These panels can be used in parallel to detect clinically relevant fusions, CNVs, SNVs and indels from a single, low-input FFPE sample.For Research Use Only. Not for use in diagnostic procedures.
With the FusionPlex and VariantPlex parallel workflow, Archer provides the tools for in-house, comprehensive sample testing for all relevent mutations, reducing necessary input amounts, costly send outs and long turn-around times.
FusionPlex and VariantPlex assays are optimized for low-input FFPE and other clinical sample types:
Labs can go from sample-to-sequencer in under one day, enabling total turnaround time of 3-5 days from sample extraction through data processing.
Comprehensive mutation testing is performed in-house, so there is no need for sample send-outs.
Both assays use a lyophilized workflow that reduces chances of contamination and lab error.
You have one precious tissue sample.
It's small, so you don't have a lot to work with. You have an idea of what mutations you want to look for, but you worry that you'll miss something. And since you don't have that much starting material, you fear that you can't look for everything. You could send it out for comprehensive mutation testing, but they require large sample amounts. Plus, you don't want to wait weeks for results. And after all that, if the results are inconclusive, you worry that reflex testing will prolong identifying the right mutations and use up any remaining sample.
Mutations that drive oncogenesis and disease progression can be tough to identify. They arise from different molecular abnormalities, including gene fusions, copy number variations (CNVs), single-nucleotide polymorphisms (SNPs) or insertions/deletions (indels). Plus, the frequency of driver mutation types varies for each cancer type. Combined with the fact that driver mutations can be found in any of hundreds of genes, the ability to rapidly and economically characterize mutations from a large subset of potential genes independent of mutation type in a clinical setting has been untenable.
2477 55th Street, Suite 202
Boulder, CO 80301